PYPDPolyPid Ltd.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $5.21 · now $5.21 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, PYPD has typically landed between $3.74 and $6.46 — a range of −28.2% to +24.0% from the issuance price $5.21.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,531 overlapping 1 month windows · 2020-06-262026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($5.21) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where PYPD has typically landed a month from the 2026-09-16 close of $5.21 — the range is history, not a prediction.

$3.74worst · -28.2%$6.46best · +24.0%
  • now $5.21 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $5.06 (-2.8%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $4.59$5.54
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $3.74$6.46
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,531 windows spanning 2020-06-26 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2022-08-24−83.0%−83.2%+1.3%
2022-08-23−82.7%−82.7%+3.9%
2022-08-25−82.6%−83.0%+2.1%
3 best
2023-12-26+81.4%+0.0%+114.4%
2023-12-28+72.5%−0.5%+102.6%
2023-12-22+70.6%−5.2%+103.1%

1,531 overlapping windows · 2020-06-262026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~7 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
50%
+8.0%
n=6
Feb
33%
−2.1%
n=6
Mar
33%
−6.9%
n=6
Apr
67%
−1.3%
n=6
May
50%
+0.8%
n=6
Jun
33%
+0.7%
n=6
Jul
14%
−8.7%
n=7
Aug
43%
+3.2%
n=7
Sep
14%
−22.7%
n=7
Oct
17%
−6.0%
n=6
Nov
67%
+2.8%
n=6
Dec
17%
−10.4%
n=6

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$6$3↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

10 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-07-15Akselbrad Dikla CzaczkesdirectorAward / grant149,000149,000Form 4
2026-07-15Barenholz YechezkeldirectorAward / grant9,1329,132Form 4
2026-07-15BenAmram JosephdirectorAward / grant9,1329,132Form 4
2026-07-15Dror-Darwish NirdirectorAward / grant9,1329,132Form 4
2026-07-15Krinsky ItzhakdirectorAward / grant9,1329,132Form 4
2026-07-15Story BrookedirectorAward / grant9,1329,132Form 4
2026-07-15Stein Robert BenjamindirectorAward / grant9,1329,132Form 4
2026-05-11Hazan Dalit FellousofficerAward / grant75,00075,000Form 4
2026-05-11Missulawin JonathanofficerAward / grant49,00049,000Form 4
2026-05-11Warshavsky OriofficerAward / grant46,00046,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.